Alcohol Use Disorder Market is Expected to Showcase a Significant Growth During the Forecast Period (2023-2032), Predicts DelveInsight | MediciNova, Bioprojet, Pfizer, Organon, Gilead, Opiant Pharma, ADial Pharmaceuticals, R-Pharma, Synergy Research

The Alcohol Use Disorder market size in the seven major markets was USD 564.0 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 8.8% for the study period (2019-2032). As per DelveInsight, the Alcohol Use Disorder Market is anticipated to evolve immensely in the coming years owing to the expected approval of emerging therapies and the increase in the diagnosed prevalent population of AUD in the 7MM.

DelveInsight's "Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Alcohol Use Disorder Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Alcohol Use Disorder therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Alcohol Use Disorder treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Alcohol Use Disorder: An Overview
Alcohol use disorder (AUD) is one of the most common substance use disorders characterized by excessive, uncontrollable drinking that impacts a person physically, emotionally, and socially. It can be mild, moderate, or severe, based on the number of symptoms experienced by an individual. A person with AUD may experience both intoxication and withdrawal symptoms such as unstable moods, poor judgment, slurred speech, problems with attention or memory, poor coordination, sweating, rapid heartbeat, hand tremors, seizures, etc.

It has multiple causes, with genetic, physiological, psychological, and social factors all impacting an individual's behavior. Healthcare professionals use the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria to diagnose and determine the severity of AUD and it requires that at least two of the 11 DSM-V diagnostic criteria are present to confirm the diagnosis.

The main goal of AUD treatment is either complete abstinence or reduction of heavy drinking. The current treatment options include medication-assisted treatment, behavioral interventions, detox, and psychosocial assistance from rehab and support groups. The mainstay treatment though is psychosocial intervention but with high relapse rates, the best way is to combine pharmacotherapy with psychosocial counseling and intervention.

Alcohol Use Disorder Market Key Facts
• The United States accounts for the largest Alcohol Use Disorder market size, in comparison to the EU-5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
• Among the EU5 countries, Germany had the highest Alcohol Use Disorder market size with approximately USD 35.7 million in 2021. This is expected to further increase, with Germany estimated to capture the maximum market, followed by the UK in 2032.
• The Alcohol Use Disorder market size in Japan was valued at approximately USD 10.2 million in 2021.
• In 2021, the 12-month diagnosed prevalent cases of Alcohol Use Disorder were estimated to be 25,027,206 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.6% during the study period (2019-2032).
• Among the 7MM, the United States accounted for nearly 58% of the total 12-month diagnosed prevalent cases of Alcohol Use Disorder in the 7MM in the year 2021 which is expected to increase further by 2032.
• Among the EU5 countries, Germany had the highest 12-month diagnosed prevalent cases of Alcohol Use Disorder with 2,541,460 cases in 2021, while Spain had the lowest 12-month diagnosed prevalent population of Alcohol Use Disorder with 1,326,329 cases in 2021.
• In 2021, the 12-month diagnosed prevalent population of Alcohol Use Disorder in Japan was found to be 1,161,931, which is expected to change for the study period of 2019-2032.

Discover How the Alcohol Use Disorder Market Will Grow by 2032:
https://www.delveinsight.com/report-store/alcohol-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Alcohol Use Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Alcohol Use Disorder therapies in the market. It also provides a detailed assessment of the Alcohol Use Disorder market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Alcohol Use Disorder drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Alcohol Use Disorder Epidemiology
The epidemiology section covers detailed insights into the historical, and current Alcohol Use Disorder patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Alcohol Use Disorder Epidemiology Segmented as -
• 12-month Diagnosed Prevalent Cases of AUD in the 7MM [2019-2032]
• Type-specific Diagnosed Prevalent Cases of AUD in the 7MM [2019-2032]
• Gender-specific Diagnosed Prevalent Cases of AUD in the 7MM [2019-2032]

Get Key Insights Into the Evolving Alcohol Use Disorder Epidemiology Trends @
https://www.delveinsight.com/report-store/alcohol-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Alcohol Use Disorder Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alcohol Use Disorder market or expected to be launched during the study period. The analysis covers the market share by Alcohol Use Disorder drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Alcohol Use Disorder Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Alcohol Use Disorder Therapeutics Assessment
There is a need for personalized medicine which reduces the craving for alcohol. Though, there have been efforts to use precision medicine approaches to tailor pharmacotherapies to individuals with different presentations of AUD. But still, there is a large treatment gap in alcohol dependence, and current treatments are only moderately effective in preventing relapse. The need for abstinence and the associated social stigma further complicates the treatment. New treatment modalities, allowing for reduction of alcohol consumption as a treatment goal, are needed.

The expected launch of potential therapies that include AD04 (ondansetron) (Adial Pharmaceuticals), CORT118335 (mifepristone) (Corcept Therapeutics), and MN-166 (ibudilast) (MediciNova) may address the unmet need in the Alcohol Use Disorder market, increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of AUD.

Leading Companies in the Alcohol Use Disorder Therapeutics Market Include
• ADial Pharmaceuticals
• R-Pharm|Synergy Research
• Arbor Pharmaceuticals
• Laboratorio Farmaceutico
• Gilead Sciences
• Kinnov Therapeutics
• Opiant Pharmaceuticals
• MediciNova
• Bioprojet
• Corcept Therapeutics
• Pfizer
• Dicerna Pharmaceuticals, Inc.
• Organon
• Confluence Pharmaceuticals
And Many Other

Emerging and Marketed Alcohol Use Disorder Therapies Covered in the Report Include
• AD04/Ondansetron: Adial Pharmaceuticals
• ANS-6637: Amygdala Neurosciences
• BXCL501: BioXcel Therapeutics
• CYB003: Cybin
• DCR-AUD: Dicerna Pharmaceuticals
• GET73: Laboratorio Farmaceutico
• Ibudilast/MN-166: MediciNova
• KT 110: Kinnov Therapeutics
• MAP4343: Mapreg
• PT150: Pop Test Oncology
• WIL-1903: Whanin Pharmaceutical
And Many More

Learn More About the Emerging Therapies & Key Companies in the Alcohol Use Disorder Therapeutics Market:
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Alcohol Use Disorder Competitive Intelligence Analysis
4. Alcohol Use Disorder Market Overview at a Glance
5. Alcohol Use Disorder Background and Overview
6. Alcohol Use Disorder Patient Journey
7. Alcohol Use Disorder Epidemiology and Patient Population
8. Alcohol Use Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Alcohol Use Disorder Unmet Needs
10. Key Endpoints of Alcohol Use Disorder Treatment
11. Alcohol Use Disorder Marketed Products
12. Alcohol Use Disorder Emerging Therapies
13. Alcohol Use Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Alcohol Use Disorder Market Outlook (7 major markets)
16. Alcohol Use Disorder Access and Reimbursement Overview
17. KOL Views on the Alcohol Use Disorder Market.
18. Alcohol Use Disorder Market Drivers
19. Alcohol Use Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Dementia with Diabetes Market
https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast

Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market

Venous Stenosis Market
https://www.delveinsight.com/report-store/venous-stenosis-market

Bronchial Hyperreactivity Market
https://www.delveinsight.com/report-store/bronchial-hyperreactivity-market

Pegfilgrastim Biosimilar
https://www.delveinsight.com/report-store/pegfilgrastim-biosimilar-insight

Cytokine Release Syndrome Market
https://www.delveinsight.com/report-store/cytokine-release-syndrome-market

Primary Progressive Multiple Sclerosis (PPMS) Market
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market

Singapore Healthcare Outlook
https://www.delveinsight.com/report-store/singapore-healthcare-outlook-report

Hematuria Market
https://www.delveinsight.com/report-store/hematuria-market

Varicose Ulcer Market
https://www.delveinsight.com/report-store/varicose-ulcer-market

Anaplastic Astrocytoma Market
https://www.delveinsight.com/report-store/anaplastic-astrocytoma-market

Lymphoedema Market
https://www.delveinsight.com/report-store/lymphoedema-market

Morquio Syndrome Market
https://www.delveinsight.com/report-store/morquio-syndrome-market

Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market

Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market

Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market

Diabetes Market
https://www.delveinsight.com/report-store/diabetes-market

Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

Urinary Incontinence Market
https://www.delveinsight.com/report-store/urinary-incontinence-market

Seborrhoeic Dermatitis Market Substance (Drug) Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market

Artificial Cornea and Corneal Implant Market
https://www.delveinsight.com/report-store/artificial-cornea-and-corneal-implant-market

Prosthetic Heart Valve Market
https://www.delveinsight.com/report-store/prosthetic-heart-valve-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.